Sandoz Group AG

Fr 83.78As of Sun 8 Nov 2026, 12:00 UTC

SWX:SDZHealthcare

Country Switzerland

PE (Fwd) •••

TSR 3Y CAGR 54.24%

Div yield 0.95%

ROE 7.25%

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.40

PE TTM 70.61

TSR TTM 58.50%

Mkt cap Fr 36.25B

ROIC 6.43%

SE Grade™

Value

Quality

Moat

Consensus

Reference

Fr 85

1.69%

(67.74%)

Hold 1|3|7|12|2

TTM

FYE 31 Dec USD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

1.510

Revenue$B

4.394

4.558

4.731

4.877

5.024

5.319

5.437

5.573

5.859

5.948

1.656

3.43%

3.30%

20.69

Revenue growth%

10.86

11.93

10.29

9.97

10.81

9.68

10.74

9.01

6.44

5.63

4.57

9.01

10.13

5.27

Gross margin%

4.71

6.70

8.12

9.00

6.15

6.32

6.81

4.90

4.43

6.95

15.93

6.32

6.51

6.90

Operating margin%

27.14

24.99

25.86

27.87

25.20

26.09

27.61

25.62

26.29

28.12

22.64

26.29

26.19

8.32

Net margin%

17.65

14.77

17.68

17.83

17.16

17.00

18.45

17.24

15.21

18.18

11.39

17.24

17.45

33.30

P/E ratio (avg)x

27.49

25.88

28.25

24.99

27.21

29.31

27.72

24.74

27.28

29.70

29.37

27.72

27.38

27.69

EV/EBITx

14.37

14.44

15.73

17.95

21.27

21.35

24.55

27.65

27.47

32.84

19.88

27.47

21.31

29.91

FCF yield (avg)%

12.55

15.05

16.92

15.98

17.20

15.23

17.04

17.75

16.48

16.85

23.73

16.85

16.67

26.94

FCF margin%

20.99

23.41

23.28

22.99

24.17

22.87

21.79

19.41

22.36

19.47

25.22

21.79

22.61

1.396

FCF / Net incomex

1.148

1.272

1.456

1.642

1.855

1.786

1.835

1.922

2.242

2.219

1.570

1.922

1.811

18.63

ROIC%

19.40

17.70

17.53

15.96

14.99

12.93

12.75

13.19

10.86

11.05

7.12

12.75

14.09

2.95

Return on equity%

28.86

30.67

29.49

27.99

25.08

26.17

24.87

23.95

26.33

27.22

13.63

26.17

26.78

5.67

Return on assets%

33.25

31.38

30.79

33.29

35.72

35.31

36.84

39.62

37.02

38.79

29.61

37.02

35.51

3.52

EPS$

5.20

5.95

6.36

5.87

6.44

7.33

7.14

7.63

8.18

8.31

3.79

5.24%

3.89%

—

16.56

EPS growth%

28.33

28.00

26.42

29.31

31.15

30.12

32.88

32.61

32.12

30.79

26.80

32.12

30.46

9.30

Bookvalue per sh$

6.79

6.41

7.01

7.72

7.96

9.17

9.63

10.06

10.52

8.30

6.37%

4.41%

—

1.74

FCF per share$

9.54

10.48

10.89

11.78

11.41

9.96

10.03

8.92

8.10

8.27

4.54

(6.22%)

(0.62%)

—

7.85

Dividend per sh$

5.99

5.68

6.14

5.75

6.09

5.85

5.07

5.17

4.57

4.36

10.08

(6.46%)

(4.45%)

—

5.91

Div yield (avg)%

32.39

32.57

32.33

29.68

32.04

31.72

34.37

36.82

36.36

35.30

26.17

35.30

32.48

29.66

Payout ratio%

8.54

9.36

10.49

12.36

11.74

10.24

11.78

14.67

13.39

12.06

25.64

12.06

11.76

0.420

Shares (diluted)B

0.784

0.846

1.025

1.142

1.118

1.354

1.621

1.594

1.612

1.908

0.437

11.29%

10.30%

26.43

Buyback yield%

12.47

14.86

16.86

17.03

14.76

14.43

15.76

18.61

15.83

14.47

16.55

15.76

15.31

0.476

D/E ratiox

1.399

1.408

1.361

1.226

1.120

1.059

1.116

1.011

0.923

0.925

1.565

1.011

1.118

2.277

Enterprise value$B

4.009

4.361

4.987

4.999

5.000

5.085

5.306

5.055

4.667

4.591

6.294

(1.69%)

0.89%

1.439

LT debt$B

2.452

2.692

2.512

2.442

2.466

2.401

2.260

2.363

2.512

2.626

5.384

1.26%

0.46%

Peers (US$44.46B)

Cap (US$)

Novartis AG

308.2B

30.48x

Galderma Group AG

54.84B

64.97x

Siegfried Holding AG

3.868B

18.46x

Sun Pharmaceutical…

47.52B

40.70x

Capital

TTM

10Y

Leveragex

1.903

—

EBIT/Intx

0.792

0.042

0.044

Own earn%

(28.32)

30.97

42.68

Sh yield%

32.35

50.13

48.31

Owners

Insiders/Inst%

11.40

25.88

Short interest%

3.80

SBC / revenue%

4.74

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

25–28

$1 testx

−0.1

Incr. ROIC%

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$5.948B

3.30%

1.00×

Cost of revenue

$4.127B

3.21%

0.99×

Operating expenses

$1.365B

3.64%

1.03×